4SCAR T cells
PreclinicalCell therapy
4SCAR T cells is one of 24 therapeutic programs targeting Breast Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
2
Active Trials
23
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Adenocard
AstellasPreclinical
Zolymbus
AbbViePreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4SCAR T cells. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy
- Highest Phase
- Preclinical[1]